Srs Capital Advisors, Inc. 4 D Molecular Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.48 Billion
- Q1 2025
A detailed history of Srs Capital Advisors, Inc. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 628 shares of FDMT stock, worth $2,185. This represents 0.0% of its overall portfolio holdings.
Number of Shares
628Holding current value
$2,185% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FDMT
# of Institutions
128Shares Held
43.5MCall Options Held
25.8KPut Options Held
33.4K-
Black Rock Inc. New York, NY4.9MShares$17 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$15.9 Million0.31% of portfolio
-
Bvf Inc San Francisco, CA4.56MShares$15.9 Million0.65% of portfolio
-
Goldman Sachs Group Inc New York, NY4.17MShares$14.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$9.6 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $113M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...